Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
Abstract Metastatic non-small-cell lung cancer (NSCLC) with activating EGFR mutations responds very well to first and second generation tyrosine-kinase inhibitors (TKI) including gefitinib, erlotinib and afatinib. Unfortunately, drug resistance will eventually develop and about half of the cases are...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/48baaceb101f44bbbb0e692bec36675e |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|